VolitionRX Ltd Company Profile (NYSEMKT:VNRX)

About VolitionRX Ltd (NYSEMKT:VNRX)

VolitionRX Ltd logoVolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease. The Company's Nucleosomics biomarker platform is a technology that is used for a range of cancers. The Company is developing Nucleosomics tests for various cancers, including colorectal, pancreatic, lung and aggressive prostate. The Company's NuQ blood assays fall into over five types, which include NuQ-X, NuQ-V, NuQ-M, NuQ-A and NuQ-T. It has developed approximately two blood assays in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:VNRX
  • CUSIP: N/A
  • Web: N/A
Capitalization:
  • Market Cap: $89.62 million
  • Outstanding Shares: 26,360,000
Average Prices:
  • 50 Day Moving Avg: $3.69
  • 200 Day Moving Avg: $4.19
  • 52 Week Range: $3.05 - $5.86
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.96
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.71 per share
  • Price / Book: 4.79
Profitability:
  • EBIDTA: ($12,790,000.00)
Misc:
  • Average Volume: 28,044 shs.
  • Beta: -1.58
  • Short Ratio: 10.07
 

Frequently Asked Questions for VolitionRX Ltd (NYSEMKT:VNRX)

What is VolitionRX Ltd's stock symbol?

VolitionRX Ltd trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "VNRX."

How were VolitionRX Ltd's earnings last quarter?

VolitionRX Ltd (NYSEMKT:VNRX) issued its earnings results on Thursday, May, 11th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. View VolitionRX Ltd's Earnings History.

Where is VolitionRX Ltd's stock going? Where will VolitionRX Ltd's stock price be in 2017?

2 brokers have issued 12-month target prices for VolitionRX Ltd's stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate VolitionRX Ltd's stock price to reach $10.00 in the next year. View Analyst Ratings for VolitionRX Ltd.

Who are some of VolitionRX Ltd's key competitors?

Who are VolitionRX Ltd's key executives?

VolitionRX Ltd's management team includes the folowing people:

  • Martin Charles Faulkes, Executive Chairman of the Board
  • Cameron John Reynolds, President, Chief Executive Officer, Director
  • David Matthew Kratochvil, Chief Financial Officer, Treasurer
  • Louise Dayas, Chief Marketing and Communications Officer
  • Jason Bradley Terrell, Chief Medical Officer and Head of US Operations
  • Rodney Gerard Rootsaert, Secretary
  • Alan Colman, Director
  • Edward W. Futcher Ph.D., Independent Director
  • Guy Archibald Innes, Independent Director
  • Habib Skaff, Independent Director

Who owns VolitionRX Ltd stock?

VolitionRX Ltd's stock is owned by a number of of retail and institutional investors. Top institutional investors include Lagoda Investment Management L.P. (11.25%), Southpoint Capital Advisors LP (3.06%), Vanguard Group Inc. (0.78%), Geode Capital Management LLC (0.39%) and Morgan Stanley (0.23%). Company insiders that own VolitionRX Ltd stock include Cameron John Reynolds and David Matthew Kratochvil. View Institutional Ownership Trends for VolitionRX Ltd.

Who sold VolitionRX Ltd stock? Who is selling VolitionRX Ltd stock?

VolitionRX Ltd's stock was sold by a variety of institutional investors in the last quarter, including Lagoda Investment Management L.P. and Morgan Stanley. View Insider Buying and Selling for VolitionRX Ltd.

Who bought VolitionRX Ltd stock? Who is buying VolitionRX Ltd stock?

VolitionRX Ltd's stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View Insider Buying and Selling for VolitionRX Ltd.

How do I buy VolitionRX Ltd stock?

Shares of VolitionRX Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VolitionRX Ltd's stock price today?

One share of VolitionRX Ltd stock can currently be purchased for approximately $3.40.


MarketBeat Community Rating for VolitionRX Ltd (NYSEMKT VNRX)
Community Ranking:  5.0 out of 5 (    )
Outperform Votes:  39 (Vote Outperform)
Underperform Votes:  0 (Vote Underperform)
Total Votes:  39
MarketBeat's community ratings are surveys of what our community members think about VolitionRX Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for VolitionRX Ltd (NYSEMKT:VNRX) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.00

Analysts' Ratings History for VolitionRX Ltd (NYSEMKT:VNRX)
Show:
DateFirmActionRatingPrice TargetDetails
3/14/2017HC WainwrightReiterated RatingBuy$10.00View Rating Details
9/7/2016Rodman & RenshawLower Price TargetBuy$12.00 -> $10.00View Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for VolitionRX Ltd (NYSEMKT:VNRX)
Earnings by Quarter for VolitionRX Ltd (NYSEMKT:VNRX)
Earnings History by Quarter for VolitionRX Ltd (NYSEMKT:VNRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/20173/31/2017($0.14)($0.13)ViewN/AView Earnings Details
8/11/2016Q216($0.12)($0.13)ViewListenView Earnings Details
5/13/2016Q116($0.13)($0.13)ViewN/AView Earnings Details
11/4/2015Q315($0.13)($0.16)$0.20 millionViewN/AView Earnings Details
8/11/2015Q215($0.14)($0.10)$0.11 millionViewN/AView Earnings Details
5/12/2015Q115($0.14)($0.12)ViewN/AView Earnings Details
11/6/2014($0.09)($0.13)$0.13 million$0.02 millionViewN/AView Earnings Details
5/27/2014($0.10)($0.09)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for VolitionRX Ltd (NYSEMKT:VNRX)
Current Year EPS Consensus Estimate: $-0.55 EPS
Next Year EPS Consensus Estimate: $-0.57 EPS

Dividends

Dividend History for VolitionRX Ltd (NYSEMKT:VNRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for VolitionRX Ltd (NYSEMKT:VNRX)
Insider Trades by Quarter for VolitionRX Ltd (NYSEMKT:VNRX)
Institutional Ownership by Quarter for VolitionRX Ltd (NYSEMKT:VNRX)
Insider Trades by Quarter for VolitionRX Ltd (NYSEMKT:VNRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/5/2016David Matthew KratochvilCFOBuy10,000$5.00$50,000.00View SEC Filing  
5/20/2016Cameron John ReynoldsCEOSell3,390$3.54$12,000.60View SEC Filing  
5/15/2015Cameron John ReynoldsCEOBuy1,500$3.33$4,995.00View SEC Filing  
2/11/2015Guy Archibald InnesDirectorBuy50,000$3.75$187,500.00View SEC Filing  
9/15/2014Martin Charles FaulkesDirectorBuy5,000$2.16$10,800.00View SEC Filing  
9/3/2014Rodney Gerard RootsaertInsiderSell28,000$1.80$50,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for VolitionRX Ltd (NYSEMKT:VNRX)
Latest Headlines for VolitionRX Ltd (NYSEMKT:VNRX)
Source:
DateHeadline
finance.yahoo.com logoVolitionRx Limited to Present at Multiple Investor Conferences in June
finance.yahoo.com - May 26 at 8:24 AM
finance.yahoo.com logoVNRX: Closing In On EU Launch, Asia Could Be Next
finance.yahoo.com - May 23 at 7:58 PM
finance.yahoo.com logoA new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition's Nu.Q(TM) assays
finance.yahoo.com - May 18 at 10:29 AM
americanbankingnews.com logoVolitionRX Ltd (VNRX) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 12 at 11:26 AM
finance.yahoo.com logoVolitionRx Limited Announces First Quarter 2017 Financial Results and Business Update
finance.yahoo.com - May 12 at 4:10 AM
finance.yahoo.com logoVolitionRx Limited Announces Final Results from 8000 Patient Clinical Trial in Denmark to Evaluate the Performance of its Nu.Q(TM) Triage Test
finance.yahoo.com - May 9 at 9:44 AM
americanbankingnews.com logoVolitionRX Ltd (VNRX) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - May 9 at 7:06 AM
finance.yahoo.com logoVolitionRx Limited Schedules First Quarter 2017 Earnings Conference Call and Business Update
finance.yahoo.com - May 8 at 9:00 AM
americanbankingnews.com logoVolitionRX (VNRX) Given Daily Media Impact Rating of 0.31
www.americanbankingnews.com - May 3 at 8:10 PM
finance.yahoo.com logoVolition makes progress with its Colorectal Cancer Screening Triage Test in both Asia and Europe
finance.yahoo.com - April 27 at 11:50 AM
americanbankingnews.com logoVolitionRX (VNRX) Receives Daily News Impact Rating of 0.31
www.americanbankingnews.com - April 22 at 3:13 PM
finance.yahoo.com logoVolition opens a new Research and Development facility in Belgium with a state of the art, purpose-built laboratory
finance.yahoo.com - April 21 at 8:45 PM
americanbankingnews.com logoVolitionRX (VNRX) Earns Daily News Sentiment Score of -0.15
www.americanbankingnews.com - April 18 at 9:55 AM
finance.yahoo.com logoVolitionRx Appoints David Vanston as Chief Financial Officer
finance.yahoo.com - April 11 at 8:49 AM
us.rd.yahoo.com logoVolition America, Inc. Retains Strategic Expert in Securing Non-Dilutive Funding Opportunities in the United States
us.rd.yahoo.com - March 28 at 10:42 PM
finance.yahoo.com logoVNRX: Logistics Validation And Danish Launch Could Be Upcoming
finance.yahoo.com - March 21 at 3:18 PM
finance.yahoo.com logoVolitionRx Limited Announces the Formation of Volition America, Inc.
finance.yahoo.com - March 20 at 8:18 AM
americanbankingnews.com logoVolitionRX Ltd (VNRX) Earns “Buy” Rating from HC Wainwright
www.americanbankingnews.com - March 19 at 1:26 AM
finance.yahoo.com logoVolitionRx Limited Celebrates CE Mark Announcement By Ringing Closing Bell at the New York Stock Exchange
finance.yahoo.com - March 14 at 8:12 PM
finance.yahoo.com logoVolitionRx Limited to Ring the New York Stock Exchange Closing Bell on Monday, March 13th at 4 pm Eastern Daylight Time
finance.yahoo.com - March 13 at 8:18 AM
us.rd.yahoo.com logoVolitionRx Limited Announces Full Fiscal Year 2016 Financial Results and Business Update
us.rd.yahoo.com - March 10 at 9:35 AM
biz.yahoo.com logoQ4 2016 VolitionRX Ltd Earnings Release - Before Market Open
us.rd.yahoo.com - March 10 at 9:35 AM
cnbc.com logoVolitionRX reports 4Q loss
www.cnbc.com - March 10 at 9:33 AM
finance.yahoo.com logoVolitionRx Limited to Present at the 29th Annual ROTH Conference
finance.yahoo.com - March 9 at 4:22 AM
finance.yahoo.com logoVolitionRx Limited Schedules Fourth Quarter and Full Year 2016 Earnings Conference Call and Business Update
finance.yahoo.com - March 6 at 7:51 PM
finance.yahoo.com logoA Logistics and Pathway Design Study for Volition's CE Marked NuQ(TM) Triage Test has been Commenced in the Capital Region of Denmark
finance.yahoo.com - March 3 at 5:46 AM
us.rd.yahoo.com logoVolitionRx Limited's Triage Test Results Validated in Prospective Trial
us.rd.yahoo.com - February 25 at 8:05 PM
finance.yahoo.com logoVolitionRx Limited to Attend the BTIG 2017 Medical Technology, Life Sciences, and Diagnostics Conference
finance.yahoo.com - February 23 at 11:43 PM
finance.yahoo.com logoVolitionRx Limited to Present at Source Capital Group's 2nd Annual Disruptive Growth & Healthcare Conference on February 15, 2017
finance.yahoo.com - February 10 at 6:31 AM
finance.yahoo.com logo2 Medical Companies at Forefront of Oncology Testing
finance.yahoo.com - January 8 at 6:32 AM
finance.yahoo.com logoVolitionRx Limited Strengthens Team with Key Appointment to Drive Sales and Trials in Asia
finance.yahoo.com - January 6 at 6:31 AM
finance.yahoo.com logoVNRX: Triage CE Marked. More Details Next Week at JPM Conference
finance.yahoo.com - January 4 at 4:16 PM
us.rd.yahoo.com logoVolitionRx Limited's Novel Cancer Diagnostic Test Achieves CE Marking as it Prepares for Launch Across Europe
us.rd.yahoo.com - January 4 at 7:38 AM
us.rd.yahoo.com logo9:03 am VolitionRx achieved CE marking on its Nu.Q Colorectal Cancer Screening Triage Test on December 28, 2016 as it prepares to launch across Europe
us.rd.yahoo.com - January 4 at 7:38 AM
finance.yahoo.com logoVolitionRx Limited to Present at 9th Annual Biotech Showcase Conference
finance.yahoo.com - December 28 at 8:20 AM
finance.yahoo.com logoVolitionRx Limited to Attend Citi 2016 Global Healthcare Conference
finance.yahoo.com - December 1 at 9:15 PM
finance.yahoo.com logoVNRX: More Details on Triage Strategy, Launch Still Expected in 2017
finance.yahoo.com - November 18 at 11:46 AM
finance.yahoo.com logoVolitionRx Limited to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum 2016
finance.yahoo.com - November 11 at 11:28 AM
finance.yahoo.com logoVolitionRx Limited Schedules Third Quarter 2016 Earnings Conference Call and Business Update
finance.yahoo.com - November 4 at 12:26 PM
finance.yahoo.com logoVolitionRx Limited Announces Acquisition of New Belgian Facility and Appointment of COO to Belgian Volition
finance.yahoo.com - October 26 at 11:47 AM
finance.yahoo.com logoVolitionRx Limited Announces Exercise of Over-Allotment Option by Underwriter
finance.yahoo.com - October 21 at 11:40 AM
prnewswire.com logoTriage Blood Test Data Presented to Leading International Experts at the World Endoscopy Organization's Colorectal Cancer Screening Committee
www.prnewswire.com - October 17 at 7:52 PM
finance.yahoo.com logoSeeThruEquity Issues Update on VolitionRX (VNRX) and Raises Price Target to $7.00
finance.yahoo.com - October 13 at 12:01 PM
streetinsider.com logoVolitionrx Limited (VNRX) Announces Presentation of Positive Blood Test for Colorectal Cancer Data
www.streetinsider.com - October 12 at 12:56 PM
finance.yahoo.com logoVolitionRX Ltd. to Present at The MicroCap Conference on October 24-25 in Philadelphia
finance.yahoo.com - October 11 at 7:46 PM
biz.yahoo.com logoVOLITIONRX LTD Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Mat
biz.yahoo.com - October 11 at 7:46 PM
prnewswire.com logoVolitionRx Limited Announces Pricing of Public Offering of Common Stock
www.prnewswire.com - October 1 at 8:45 AM
finance.yahoo.com logoVolitionRx Limited Announces Proposed Public Offering of Common Stock
finance.yahoo.com - September 30 at 7:28 AM
finance.yahoo.com logoVNRX: Initial Product Will Be Complement To Current CRC Screens
finance.yahoo.com - September 7 at 8:04 PM
finance.yahoo.com logoVolitionRx to Attend Several Conferences in September
finance.yahoo.com - September 7 at 11:52 AM

Social

This page was last updated on 5/29/2017 by MarketBeat.com Staff